Interventions for preventing and treating kidney disease in Henoch-Schönlein Purpura (HSP)

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 8, 2015, Pages

  Hahn, Deirdre ^a   Hodson, Elisabeth M ^b,c   Willis, Narelle S ^c,d   Craig, Jonathan C ^c,d  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d University of Sydney   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORINE; FOSINOPRIL; HEPARIN; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PLACEBO; PREDNISONE; STEROID; ANTITHROMBOCYTIC AGENT; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT;

ACUTE KIDNEY FAILURE; ANAPHYLACTOID PURPURA; BEHAVIOR DISORDER; DISEASE SEVERITY; DRUG EFFICACY; END STAGE RENAL DISEASE; FOLLOW UP; HEMATURIA; HUMAN; INFECTION; KIDNEY DISEASE; NEPHRITIS; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROTEINURIA; RECURRENT DISEASE; REMISSION; REVIEW; SYSTEMATIC REVIEW; CHILD; COMPLICATION; KIDNEY DISEASES; META ANALYSIS; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADRENAL CORTEX HORMONES; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; PLATELET AGGREGATION INHIBITORS; PURPURA, SCHOENLEIN-HENOCH; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84991264541     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD005128.pub3     Document Type: Review

References (82)

1. Pillebout E, Alberti C, Guillevin L, Ouslimani A, Thervet E, CESAR study group. Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schonlein Purpura. Kidney International 2010;78(5):495-502. [MEDLINE: 20505654]
2. Pillebout E, Alberti C, Guillevin L, Thervet E, CESAR Study Group. Prospective randomized study of cyclophosphamide and steroid versus steroid alone therapy in adult patients with severe Henoch Schonlein Purpura (HSP) [abstract no: SA275]. World Congress of Nephrology; 2009 May 22-26; Milan, Italy. 2009.
3. Dudley J, Smith G, Llewellyn-Edwards A, Tizard EJ. Randomised placebo controlled trial to assess the role of early prednisolone on the development and progression of Henoch-Schonlein Purpura Nephritis [abstract no: 270 (FC)]. Pediatric Nephrology 2007;22(9):1457. [CENTRAL: CN-00691227]
4. Dudley J, Smith G, Llewelyn-Edwards A, Bayliss K, Pike K, Tizard J. Randomised, double-blind, placebo-controlled trial to determine whether steroids reduce the incidence and severity of nephropathy in Henoch-Schonlein Purpura (HSP). Archives of Disease in Childhood 2013;98(10):756-63. [MEDLINE: 23845696]
5. Dudley J, Smith GC, Llewellyn-Edwards A, Tizard J. Randomised placebo controlled trial to assess the role of early prednisolone on the development and progression of Henoch-Schonlein Purpura nephritis [abstract no: SA-FC056]. Journal of the American Society of Nephrology 2007;18(Abstracts):47A.
6. Fuentes Y, Valverde S, Velasquez-Jones L, Romero B, Ramón G, Medeiros M. Comparison of azathioprine vs mofetil mycophenolate for Henoch-Schonlein nephritis treatment [abstract]. Pediatric Nephrology 2010;25(9):1802.
7. He YY, Hongmei S, Lihua S, Min W. Preventive value of heparin on the occurrence of nephropathy in Henoch-Schoenlein Purpura: a randomized controlled clinical trial [abstract no: 0364]. 23rd International Congress of Pediatrics; 2001 Sep 9 - 14; Beijing, China. 2001.
8. He YY, Pan W, Song HM, Wei M, Zhu CY. Preventive effect of heparin on the development of nephropathy in Henoch-Schoenlein purpura-a randomized controlled clinical trial. Chinese Journal of Pediatrics 2002;40(2):99-102. [CENTRAL: CN-00415840]
9. Huber AM, King J, McLaine P, Klassen T, Pothos M. A randomized, placebo-controlled trial of prednisone in early Henoch Schonlein purpura [ISRCTN85109383]. BMC Medicine 2004;2:7. [MEDLINE: 15059282]
10. Islek I, Sezer T, Totan M, Cakir M, Kucukoduk S. The effect of profilactic prednisolon therapy on renal involvement in henoch schonlein vasculitis. XXXVI Congress of the European Renal Association European Dialysis & Transplant Association; 1999 Sep 5-8; Madrid (Spain). 1999:103. [CENTRAL: CN-00484464]
11. Jauhola O, Ronkainen J, Ala-Houhala M, Autio-Harmainen H, Holtta T, Jahnukainen T, et al. Cyclosporine A (CyA) versus MP pulses (MP) in severe Henoch-Schoenlein nephritis (HSN): outcome after 2 year follow-up [abstract no: O05]. Pediatric Nephrology 2008;23(9):1584.
12. Jauhola O, Ronkainen J, Autio-Harmainen H, Koskimies O, Ala-Houhala M, Arikoski P, et al. Cyclosporine A vs. methylprednisolone for Henoch-Schonlein nephritis: a randomized trial. Pediatric Nephrology 2011;26(12):2159-66. [MEDLINE: 21626222]
13. Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Holtta T, et al. Clinical course of extrarenal symptoms in Henoch-Schonlein purpura: a 6-month prospective study. Archives of Disease in Childhood 2010;95(11):871-6. [MEDLINE: 20371584]
14. Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Holtta T, et al. Renal manifestations of Henoch-Schonlein purpura in a 6-month prospective study of 223 children. Archives of Disease in Childhood 2010;95(11):877-82. [MEDLINE: 20852275]
15. Ronkainen J, Ala-Houhala M, Antkainen M, Jahnukainen T, Koskimies O, Merenmies J, et al. Cyclosporine A (CyA) versus MP pulses (MP) in the treatment of severe Henoch-Schonlein Nephritis (HSN) [abstract no: COD. PP38]. Pediatric Nephrology 2006;21(10):1531. [CENTRAL: CN-00689778]
16. Mollica F, Li Volti S, Garozzo R, Russo G. Effectiveness of early prednisone treatment in preventing the development of nephropathy in anaphylactoid purpura. European Journal of Pediatrics 1992;151(2):140-4. [MEDLINE: 1343079]
17. Peratoner L, Longo F, Lepore L, Freschi P. Prophylaxis and therapy of glomerulonephritis in the course of anaphylactoid purpura. The results of a polycentric clinical trial. Acta Paediatrica Scandinavica 1990;79(10):976-7. [MEDLINE: 2264475]
18. Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Holtta T, et al. Clinical course of extrarenal symptoms in Henoch-Schonlein purpura: a 6-month prospective study. Archives of Disease in Childhood 2010;95(11):871-6. [MEDLINE: 20371584]
19. Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Holtta T, et al. Outcome of Henoch-Schoenlein purpura 8 years after the treatment with placebo or prednisone at disease onset [abstract]. Pediatric Nephrology 2011;26(9):1678.
20. Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Holtta T, et al. Outcome of Henoch-Schonlein purpura 8 years after treatment with a placebo or prednisone at disease onset. Pediatric Nephrology 2012;27(6):933-9. [MEDLINE: 22311342]
21. Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Holtta T, et al. Renal manifestations of Henoch-Schonlein purpura in a 6-month prospective study of 223 children. Archives of Disease in Childhood 2010;95(11):877-82. [MEDLINE: 20852275]
22. Ronkainen J, Koskimies O, Ala-Houhala M, Antkainen M, Merenmies J, Rajantie J, et al. Early prednisone therapy in Henoch-Schonlein purpura: a randomized double-blind, placebo-controlled trial. Journal of Pediatrics 2006;149(2):241-7. [MEDLINE: 16887443]
23. Tarshish P, Bernstein J, Edelmann C. Henoch-Schonlein purpura (HSP) nephritis: efficacy of cytoxan (C) & natural history. Report of the ISKDC [abstract]. Pediatric Research 2001;49(4):421A. [CENTRAL: CN-00486109]
24. Tarshish P, Bernstein J, Edelmann CM Jr. Henoch-Schonlein purpura nephritis: course of disease and efficacy of cyclophosphamide. Pediatric Nephrology 2004;19(1):51-6. [MEDLINE: 14634864]
25. Xu J, Cong H, Sheng Y. Efficacy of fosinopril on proteinuria in children with Henoch-Schonlein purpura nephritis. Zhongguo Dangdai Erke Zazhi 2009;11(3):229-30. [MEDLINE: 19292967]
26. Yoshimoto M, Ito H, Shindo S, Yamashita F. Evaluation of the preventive role of dipyridamole and aspirin against renal complication in Schonlein-Henoch purpura [abstract]. Pediatric Nephrology 1987;1:C47. [CENTRAL: CN-00445875]
27. Yoshimoto M, Ito H, Shindo S, Yamashita F. Evaluation of the preventive role of dipyridamole and aspirin against renal complication in Schonlein-Henoch purpura [abstract]. Pediatric Nephrology 1987;1:C47. [CENTRAL: CN-00445875]
28. Chen T, Guo Z-P, Zhang Y-H, Gao Y. Effect of MORA bioresonance therapy in the treatment of Henoch-Schonlein purpura and influence on serum antioxidant enzymes. Journal of Clinical Dermatology 2010;39(5):283-5. [EMBASE: 2010397798]
29. Ding HL, Cheng JZ. Clinical trial of potenlin in allergic purpura of adults. Journal of Clinical Dermatology 1995;24(5):300-2. [CENTRAL: CN-00550728]
30. Erdogan O, Oner A, Aydin A, Isimer A, Demircin G, Bulbul M, et al. Lack of efficacy of vitamin e supplementation in decreasing the oxidative damage Henoch-Schonlein Purpura: a randomised controlled trial [abstract]. Nephrology Dialysis Transplantation 1999; Vol. 14, issue 9:A46. [CENTRAL: CN-00483878]
31. Fukui H, Kamitsuji H, Nagao T, Yamada K, Akatsuka J, Inagaki M, et al. Clinical evaluation of a pasteurized factor XIII concentrate administration in Henoch-Schönlein purpura. Japanese Pediatric Group. Thrombosis Research 1989; Vol. 56, issue 6:667-75. [CENTRAL: CN-00067042]
32. Hui-Lan Y. Treatment of pediatric purpuric nephritis with Tripterygium wilfordii polyglucoside and radix salviac miltiorrhizae [abstract no: P85]. Pediatric Nephrology 2001;16(8):C79. [CENTRAL: CN-00445801]
33. Hui-Lan YY. Treatment of purpuric nephritis in children with Tripterygium wilfordii polyglucoside and Radix salviae miltiorrhizae [abstract]. Pediatric Nephrology 2001;16(8):C78. [CENTRAL: CN-00445799]
34. Jia WC, Zhang YC, Wei AP. Immune functional changes in patients of acute Henoch-Schonlein purpura and regulatory effect of integrated Traditional Chinese and Western medicine on it. Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional & Western Medicine] 2001;21(8):585-7. [MEDLINE: 12575571]
35. Jiang Y. Therapeutic effect of low-dose hepacarin in the childhood anaphylactoid purpura. Journal of Pediatric Pharmacy 2003;9(4):58-9. [CENTRAL: CN-00583752]
36. Jin ZD, Wang SC, Sun YQ. Effect of Danshao granule on serum superoxide dismutase activity and malonyldialdehyde content in children with Henoch-Schonlein purpura nephritis. Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional & Western Medicine] 2003;23(12):905-7. [MEDLINE: 14714360]
37. Kim PK, Jeong HJ, Kim KS, Lee JK, Lee JS, Choi IJ. Rifampin therapy in Henoch-Schonlein Purpura nephritis accompanied by the nephrotic syndrome [abstract]. 10th International Congress of Nephrology; 1987 Jul 26-31; London, UK. 1987:18.
38. Lee JS, Shin J, Park JM, Shin YH, Jeong HJ. Can azathioprine and steroids alter the progression of severe Henoch-Schoenlein nephritis in children?. Nephrology Dialysis Transplantation 2005;20(Suppl 5):v221.
39. Shin JI, Park JM, Shin YH, Kim JH, Lee JS, Jeong HJ. Can azathioprine and steroids alter the progression of severe Henoch-Schoenlein nephritis in children? [abstract no: M-PO30047]. Nephrology 2005;10(Suppl):A50.
40. Liu CS, Gong ZZ, Xiang SH. Clinical study on integrative Chinese and Western medicine in treating allergic purpura and preventing renal impairment. Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional & Western Medicine] 2004;24(8):701-3. [MEDLINE: 15366592]
41. Liu QC, Wu WH, Wu DY, Feng XW, Ma YH, Li JY, et al. Clinical observation on the treatment of childhood refractory idiopathic thrombocytopenic purpura with Dihuang Zhixue capsule. Chinese Journal of Integrative Medicine 2008;14(2):132-6. [MEDLINE: 18679605]
42. Wang ZW, Lu Y, Zhen XF. Effect of herbs in early intervention of children with Henoch-Schonlein purpura nephritis. Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional & Western Medicine] 2011;31(4):504-7. [MEDLINE: 21608223]
43. Xie XL, Kou SR, Xu YH, Li CY. Effect of composite salvia injection on platelet parameters in children with anaphylactoid purpura. Chinese Journal of Integrative Medicine 2009;15(2):149-51. [MEDLINE: 19407955]
44. Yang HJ, Zhuang KS, Bu TW, Mu LQ. Controlled study on therapeutic effect of vessel pricking therapy and western medication for treatment of Henoch-Schonlein purpura nephritis. Zhongguo Zhenjiu 2010;30(6):449-52. [MEDLINE: 20578379]
45. Yi H. Effect of Shenyankangfu tablet on urinary IL-6 and its therapeutic effect in children with Henoch-Schonlein purpura nephritis. Zhongguo Dangdai Erke Zazhi 2007; Vol. 9, issue 2:153-4. [MEDLINE: 17448314]
46. Zhang WZ, Zhou MJ. Clinical observation of anisodamine on treatment of anaphylactoid purpura by infused intravenously. Chinese Journal of Practical Internal Medicine 1984;4(1):26. [CENTRAL: CN-00583439]
47. Zhao H, Dou ZY, Li YQ. Preventive effect of integrative medical therapy on children Henoch-Schonleln purpura with renal impairment. Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional & Western Medicine] 2009;29(4):351-3. [MEDLINE: 19526764]
48. Ding D, Yan H, Zhen X. Effects of Chinese herbs in children with Henoch-Schonlein purpura nephritis: a randomized controlled trial. Journal of Traditional Chinese Medicine 2014;34(1):15-22. [MEDLINE: 25102685]
49. Liu ZH. To compare the efficacy, safety, tolerability and relapse of MMF vs CTX in the treatment of severe HSPN. www.clinicaltrials.gov/ct2/show/NCT00301613 (accessed 13 July 2015).
50. Wu L, Mao J, Jin X, Fu H, Shen H, Wang J, et al. Efficacy of triptolide for children with moderately severe Henoch-Schonlein purpura nephritis presenting with nephrotic range proteinuria: a prospective and controlled study in China. BioMed Research International 2013;2013:292865. [MEDLINE: 24455682]
51. Wu SH, Liao PY, Chen XQ, Yin PL, Dong L. Add-on therapy with montelukast in the treatment of Henoch-Schonlein purpura. Pediatrics International 2014;56(3):315-22. [MEDLINE: 24299021]
52. Bergstein J, Leiser J, Andreoli SP. Response of crescentic Henoch-Schoenlein purpura nephritis to corticosteroid and azathioprine therapy. Clinical Nephrology 1998;49(1):9-14. [MEDLINE: 9491279]
53. Chalmers TC, Celano P, Sacks HS, Smith H Jr. Bias in treatment assignment in controlled clinical trials. New England Journal of Medicine 1983;309(22):1358-61. [MEDLINE: 6633598]
54. Coutinho HM, Groothoff JW, Offringa M, Gruppen MP, Heymans HS. De novo malignancy after paediatric renal replacement therapy. Archives of Disease in Childhood 2001;85(6):478-483. [MEDLINE: 11719332]
55. Davin JC. Henoch-Schonlein purpura nephritis: pathophysiology, treatment and future strategy. Clinical Journal of The American Society of Nephrology: CJASN 2011;6(3):679-89. [MEDLINE: 21393485]
56. Davin JC, Coppo R. Pitfalls in recommending evidence based guidelines for a protean disease like Henoch-Schonlein purpura nephritis. Pediatric Nephrology 2013;28(10):1897-903. [MEDLINE: 23832137]
57. Du Y, Zhao C, Han W, Wu Y. Treatment of children with Henoch-Schonlein purpura nephritis with mycophenolate mofetil. Pediatric Nephrology 2012;27(5):765-71. [MEDLINE: 22081165]
58. Flynn JT, Smoyer WE, Bunchman TE, Kershaw DB, Sedman AB. Treatment of Henoch-Schonlein Purpura glomerulonephritis in children with high-dose corticosteroids plus oral cyclophosphamide. American Journal of Nephrology 2001;21(2):128-33. [MEDLINE: 11359020]
59. Foster BJ, Bernard C, Drummond KN, Sharma AK. Effective therapy for severe Henoch-Schonlein purpura nephritis with prednisone and azathioprine: a clinical and histopathologic study. Journal of Pediatrics 2000;136(3):370-5. [MEDLINE: 10700695]
60. Garner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 2002;360(9341):1197-202. [MEDLINE: 12401245]
61. Goldstein AR, White RH, Akuse R, Chantler C. Long-term follow-up of childhood Henoch Schonlein nephritis. Lancet 1992;339(8788):280-2. [MEDLINE: 1346291]
62. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: 12958120]
63. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated February 2011]. The Cochrane Collaboration. 2011. Available from www.cochrane-handbook.org.
64. Iijima R, Ito-Kariya S, Nakamura H, Yoshikowa N. Multiple combined therapy for severe Henoch Schonlein nephritis in children. Pediatric Nephrology 1998;12(3):244-8. [MEDLINE: 9630047]
65. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis & Rheumatism 2013;65(1):1-11. [MEDLINE: 23045170]
66. Kawasaki Y, Suzuki J, Suzuki H. Efficacy of methylprednisolone and urokinase pulse therapy combined with or without cyclophosphamide in severe Henoch-Schoenlein nephritis: a clinical and histopathological study. Nephrology Dialysis Transplantation 2004;19(4):858-64. [MEDLINE: 15031341]
67. KDIGO clinical practice guidelines for glomerulonephritis. Kidney International - Supplement 2012;2:139-274. [DOI: 10.1038/kisup.2012.10]
68. Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Archives of Disease in Childhood 2005;90(9):916-20. [MEDLINE: 15871983]
69. Niaudet P, Habib R. Methylprednisolone pulse therapy in the treatment of severe forms of Schonlein-Henoch purpura nephritis. Pediatric Nephrology 1998;12(3):238-43. [MEDLINE: 9630046]
70. Ronkainen J, Ala-Houhala M, Huttunen NP, Jahnukainen T, Koskimies O, Ormala T, et al. Outcome of Henoch-Schoenlein nephritis with nephrotic-range proteinuria. Clinical Nephrology 2003;60(2):80-4. [MEDLINE: 12940608]
71. Saulsbury FT. Henoch-Schonlein Purpura in children. Report of 100 patients and review of the literature. Medicine 1999;78(6):395-409. [MEDLINE: 10575422]
72. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12. [MEDLINE: 7823387]
73. Shenoy M, Ognjanovic MV, Coulthard MG. Treating severe Henoch-Schonlein and IgA nephritis with plasmapheresis alone. Pediatric Nephrology 2007;22(8):1167-71. [MEDLINE: 17530298]
74. Shin JI, Park JM, Shin YH, Hwang DH, Kim JH, Lee JS. Predictive factors for nephritis, relapse, and significant proteinuria in childhood Henoch-Schonlein purpura. Scandinavian Journal of Rheumatology 2006;35(1):56-60. [MEDLINE: 16467044]
75. Tanaka H, Suzuki K, Nakahata T, Ito E, Waga S. Early treatment with oral immunosuppressants in severe proteinuric purpura nephritis. Pediatric Nephrology 2003;18(4):347-50. [MEDLINE: 12700960]
76. Weiss PF, Feinstein JA, Luan X, Burnham JM, Feudtner C. Effects of corticosteroid on Henoch-Schonlein purpura: a systematic review. Pediatrics 2007;120(5):1079-87. [MEDLINE: 17974746]
77. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336(7644):601-5. [MEDLINE: 18316340]
78. Wyatt RJ, Hogg RJ. Evidence-based assessment of treatment options for children with IgA nephropathies. Pediatric Nephrology 2001;16(2):156-67. [MEDLINE: 11261686]
79. Zaffanello M, Brugnara M, Franchini M. Therapy for children with Henoch-Schonlein Purpura nephritis: a systematic review. Thescientificworldjournal 2007;7:20-30. [MEDLINE: 17221139]
80. Chartapisak W, Opastirakul S, Hodson EM, Willis NS, Craig JC. Interventions for preventing and treating renal disease in Henoch-Schönlein Purpura (HSP). Cochrane Database of Systematic Reviews 2005, Issue 1. [DOI: 10.1002/14651858.CD005128]
81. Chartapisak W, Opastirakul O, Willis NS, Craig JC, Hodson EM. Prevention and treatment of renal disease in Henoch-Schönlein Purpura: a systematic review. Archives of Disease in Childhood 2008;94(2):132-7. [MEDLINE: 18701559]
82. Chartapisak W, Opastirakul S, Hodson EM, Willis NS, Craig JC. Interventions for preventing and treating kidney disease in Henoch-Schönlein Purpura (HSP). Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD005128.pub2]